StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research report report published on Monday. The brokerage issued a sell rating on the medical research company’s ...
Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...
Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.
US pharma major Eli Lilly (NYSE: LLY) has announced a deal with San Diego-based Organovo Holdings (Nasdaq:ONVO), a biotech ...
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...
Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel ...